Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EBT (2016 - 2025)

Historic EBT for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to -$38.0 million.

  • Vanda Pharmaceuticals' EBT fell 48491.61% to -$38.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$138.6 million, marking a year-over-year decrease of 50489.07%. This contributed to the annual value of -$138.6 million for FY2025, which is 50489.07% down from last year.
  • According to the latest figures from Q4 2025, Vanda Pharmaceuticals' EBT is -$38.0 million, which was down 48491.61% from -$28.4 million recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' EBT registered a high of $12.6 million during Q2 2021, and its lowest value of -$38.0 million during Q4 2025.
  • In the last 5 years, Vanda Pharmaceuticals' EBT had a median value of -$890500.0 in 2023 and averaged -$5.1 million.
  • Per our database at Business Quant, Vanda Pharmaceuticals' EBT soared by 74029.01% in 2021 and then plummeted by 510333.33% in 2024.
  • Vanda Pharmaceuticals' EBT (Quarter) stood at $8.6 million in 2021, then rose by 11.65% to $9.6 million in 2022, then tumbled by 117.28% to -$1.7 million in 2023, then crashed by 291.15% to -$6.5 million in 2024, then plummeted by 484.92% to -$38.0 million in 2025.
  • Its EBT stands at -$38.0 million for Q4 2025, versus -$28.4 million for Q3 2025 and -$34.9 million for Q2 2025.